Dashboard
Manage Tickers

PCVXVaxcyte, Inc.

Nasdaq vaxcyte.com


$ 71.69 $ 4.30 (6.39 %)    

Wednesday, 15-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 71.63
$ 68.22
$ 0.00 x 0
$ 0.00 x 0
$ 68.22 - $ 71.69
$ 44.20 - $ 82.04
689,074
na
8B
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-vaxcyte
Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 15:14:41

Cantor Fitzgerald analyst Louise Chen reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight.

needham-reiterates-buy-on-vaxcyte-maintains-95-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
05/09/2024 10:43:59

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.

vaxcyte-q1-eps-085-beats-109-estimate
Vaxcyte Q1 EPS $(0.85) Beats $(1.09) Estimate
05/08/2024 21:26:30

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.09) by 22...

vaccine-player-vaxcyte-has-advantage-over-pfizer-mercks-pneumococcal-shots---analyst-says
Vaccine Player Vaxcyte Has Advantage Over ...
04/10/2024 18:42:39

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. ...

needham-reiterates-buy-on-vaxcyte-maintains-95-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
04/10/2024 11:19:40

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.

oracle-to-rally-around-40-here-are-10-top-analyst-forecasts-for-tuesday
Oracle To Rally Around 40%? Here Are 10 To...
03/12/2024 13:17:19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

mizuho-maintains-buy-on-vaxcyte-raises-price-target-to-113
Mizuho Maintains Buy on Vaxcyte, Raises Pr...
03/12/2024 11:46:59

Mizuho analyst Salim Syed maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $69 to $113.

vaxcyte-completes-enrollment-of-phase-2-study-evaluating-vax-24-for-prevention-of-invasive-pneumococcal-disease-in-infants
Vaxcyte Completes Enrollment Of Phase 2 St...
03/04/2024 13:34:06

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End...

needham-maintains-buy-on-vaxcyte-raises-price-target-to-95
Needham Maintains Buy on Vaxcyte, Raises P...
02/28/2024 11:17:38

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $73 to $95.

recap-vaxcyte-q4-earnings
Recap: Vaxcyte Q4 Earnings
02/27/2024 21:10:17

vaxcyte-q4-2023-gaap-eps-182-misses-107-estimate
Vaxcyte Q4 2023 GAAP EPS $(1.82) Misses $(...
02/27/2024 21:09:12

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.07) by ...

earnings-scheduled-for-february-27-2024
Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

vaxcyte-prices-750m-public-offering-of-10937500-common-shares-at-64share
Vaxcyte Prices $750M Public Offering Of 10...
01/31/2024 07:37:14

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankin...

vaxcyte-commences-proposed-public-offering-of-common-stock-and-pre-funded-warrants-terms-not-disclosed
Vaxcyte Commences Proposed Public Offering...
01/30/2024 21:33:38

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be...

vaxcyte-completes-enrollment-of-phase-12-study-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-aged-50
Vaxcyte Completes Enrollment Of Phase 1/2 ...
01/29/2024 13:31:37

top-pick-for-2024-analyst-bullish-on-phathom-pharmaceuticals-on-voquezna-launch-in-erosive-gerd-projecting-556m-in-sales
"Top Pick for 2024": Analyst Bullish On Ph...
01/05/2024 18:52:40

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), 

vaxcyte-provides-clinical-and-regulatory-progress-update-on-potential-best-in-class-pneumococcal-conjugate-vaccine-franchise
Vaxcyte Provides Clinical And Regulatory P...
01/04/2024 21:08:12

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review...

b-of-a-securities-maintains-buy-on-vaxcyte-raises-price-target-to-80
B of A Securities Maintains Buy on Vaxcyte...
01/02/2024 15:58:43

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $67 to ...

vaccine-player-vaxcyte-can-potentially-disrupt-pfizers-20-plus-year-near-monopoly-says-analyst
Vaccine Player Vaxcyte Can Potentially Dis...
12/07/2023 20:27:45

Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (...

mizuho-initiates-coverage-on-vaxcyte-with-buy-rating-announces-price-target-of-69
Mizuho Initiates Coverage On Vaxcyte with ...
12/07/2023 10:14:40

Mizuho analyst Salim Syed initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Buy rating and announces Price Target of $69.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION